Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission

Affiliations

¹ Medical University of Vienna, Waehringer, Guertel 18-20, A-1090, Vienna, Austria. Electronic address: Daniel.aletaha@meduniwien.ac.at.
² AbbVie Inc., 1 North Waukegan Road, North Chicago 60064, IL, USA. Electronic address: xin.wang@abbvie.com.
³ AbbVie Inc., 1 North Waukegan Road, North Chicago 60064, IL, USA. Electronic address: sheng.zhong@abbvie.com.
⁴ AbbVie NLD, Wegalaan 9, 2132 JD Hoofddorp, the Netherlands. Electronic address: stefan.florentinus@abbvie.com.
⁵ AbbVie Inc., 1 North Waukegan Road, North Chicago 60064, IL, USA. Electronic address: kelly.monastiriakos@AbbVie.com.
⁶ Medical University of Vienna, Waehringer, Guertel 18-20, A-1090, Vienna, Austria. Electronic address: josef.smolen@meduniwien.ac.at.

Comment

Daniel Aletaha et al. Semin Arthritis Rheum. 2020 Aug.

. 2020 Aug;50(4):643-644.

doi: 10.1016/j.semarthrit.2020.03.022. Epub 2020 May 5.

¹ Medical University of Vienna, Waehringer, Guertel 18-20, A-1090, Vienna, Austria. Electronic address: Daniel.aletaha@meduniwien.ac.at.
² AbbVie Inc., 1 North Waukegan Road, North Chicago 60064, IL, USA. Electronic address: xin.wang@abbvie.com.
³ AbbVie Inc., 1 North Waukegan Road, North Chicago 60064, IL, USA. Electronic address: sheng.zhong@abbvie.com.
⁴ AbbVie NLD, Wegalaan 9, 2132 JD Hoofddorp, the Netherlands. Electronic address: stefan.florentinus@abbvie.com.
⁵ AbbVie Inc., 1 North Waukegan Road, North Chicago 60064, IL, USA. Electronic address: kelly.monastiriakos@AbbVie.com.
⁶ Medical University of Vienna, Waehringer, Guertel 18-20, A-1090, Vienna, Austria. Electronic address: josef.smolen@meduniwien.ac.at.

No abstract available

Comment on

Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission.
Aletaha D, Wang X, Zhong S, Florentinus S, Monastiriakos K, Smolen JS. Aletaha D, et al. Semin Arthritis Rheum. 2020 Apr;50(2):276-284. doi: 10.1016/j.semarthrit.2019.09.005. Epub 2019 Sep 19. Semin Arthritis Rheum. 2020. PMID: 31590930 Clinical Trial.
The patient global assessment in RA precludes the majority of patients otherwise in remission to reach this status in clinical practice. Should we continue to ignore this?
Ferreira RJO, Santos E, Gossec L, da Silva JAP. Ferreira RJO, et al. Semin Arthritis Rheum. 2020 Aug;50(4):583-585. doi: 10.1016/j.semarthrit.2020.03.014. Epub 2020 May 19. Semin Arthritis Rheum. 2020. PMID: 32460149 No abstract available.
Attaining CDAI remission is the first gateway to attain Boolean remission.
Yoshii I. Yoshii I. Semin Arthritis Rheum. 2020 Aug;50(4):624-626. doi: 10.1016/j.semarthrit.2020.05.006. Epub 2020 May 25. Semin Arthritis Rheum. 2020. PMID: 32502726 No abstract available.